REGN15505
R15505-ONC-24144
Phase 2 small_molecule active
Quick answer
REGN15505 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active